Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s Votrient to be made available on NHS

GlaxoSmithKline’s Votrient to be made available on NHS

24th February 2011

GlaxoSmithKline has welcomed the decision of the National Institute for Health and Clinical Excellence (NICE) to make its cancer drug Votrient available on the NHS.

The healthcare regulator has issued positive final guidance approving the oral therapy as a first-line treatment for advanced renal cell carcinoma among patients in England and Wales.

This ruling was granted following GlaxoSmithKline's agreement to commit to a patient access scheme that will offer a discount at the point of invoice, as well as a conditional rebate depending on data from an ongoing clinical trial.

NICE stated that Votrient has been shown to deliver control of kidney cancer while allowing patients to maintain a high quality of life.

Simon Jose, general manager of GlaxoSmithKline UK, said: "Advanced kidney cancer is a devastating disease and we are pleased that through this pricing scheme we are able to offer patients rapid access to Votrient, whilst delivering value for money to the NHS."

Earlier this month, the company announced that it will be providing healthcare bodies in Kenya with discounted supplies of the pneumococcal vaccine Synflorix, as part of the Advance Market Commitment initiative.ADNFCR-8000103-ID-800425028-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.